Please Note:
The meeting previously scheduled for August 2003 in
Montreal has been rescheduled for
February
7th - 10th, 2004 in Nice,
France.
[details]
This page will remain online for historical
purposes. Symposia Overview and Topics
Each day will include 6 symposia tracks in the morning and 6 in
the evening, for a total of 48 symposia over 4 days.
Each symposium will start with a 20-minute focus
lecture by a leading expert, followed by
oral papers. Each oral paper will be
presented in a 10-minute lecture followed by a 5-minute
discussion.
The morning session starts at 11:30 and runs
until 13:00 each day. The afternoon session starts at
14:00 and runs until 15:30.
The following table lists the 48 symposia, grouped by
session. (Note: The program is subject to change.)
Symposia topics by code number and category
| Number |
Symposia Topic Name |
| Onco-genomics (day 1, morning session) |
| 1 |
Genetic instability |
| 2 |
Pharmacogenomics |
| 3 |
Signaling pathways & expression |
| 4 |
Tumor suppressor genes |
| 5 |
Susceptibility genes |
| 6 |
Gene expression profiles |
| Bio-oncology (day 1, afternoon session) |
| 7 |
Stromal epithelial interactions |
| 8 |
Growth factors & signalling |
| 9 |
Angiogenesis & inhibition |
| 10 |
Carcinogen-detoxifying enzymes |
| 11 |
Immune surveillance & response |
| 12 |
Apoptosis mechanisms |
| Environmental Cofactors (day 2, morning session) |
| 13 |
Genetic & environmental interactions |
| 14 |
Occupational surveillance |
| 15 |
Diet (incl alcohol) |
| 16 |
Xenobiotic exposures |
| 17 |
Viral infections |
| 18 |
Physical activity & weight control |
| Risk Assessment (day 2, afternoon session) |
| 19 |
Altered nuclear organization & cancer |
| 20 |
Field effects in carcinogenesis |
| 21 |
Genetic predisposition |
| 22 |
Candidate gene associations |
| 23 |
Proteomic analysis of microdissected cells |
| 24 |
Organ-specific [risk assessment] |
| Predictive Markers (day 3, morning session) |
| 25 |
Expression of HER-2/neu |
| 26 |
Chemotherapy response assays |
| 27 |
Predictive molecular pathology |
| 28 |
In vivo imaging of protease activity |
| 29 |
Tumor-associated antigens |
| 30 |
Organ & tissue-specific [predictive markers] |
| Precursors (day 3, afternoon session) |
| 31 |
Organ-specific [precursors] |
| 32 |
Benign breast disease |
| 33 |
Prostate intraepithelial neoplasia |
| 34 |
Myelodysplastic syndromes |
| 35 |
Barrett esophagus |
| 36 |
Gastric epithelial dysplasia |
| Strategies (day 4, morning session) |
| 37 |
Chemoprevention drug development |
| 38 |
Synergistic therapies |
| 39 |
Differentiation therapy |
| 40 |
Telomerase identification & inhibitors |
| 41 |
Farnesyltransferase inhibitors |
| 42 |
Chronopharmacokinetics |
| Modalities (day 4, afternoon session) |
| 43 |
Vaccine trials |
| 44 |
Preventive oncology networks |
| 45 |
Psychosocial studies |
| 46 |
Health promotion education |
| 47 |
New roles in nursing oncology |
| 48 |
Palliative care |
Please Note:
The meeting previously scheduled for August 2003 in
Montreal has been rescheduled for February
7th - 10th, 2004 in Nice,
France.
[details]
This page will remain online for historical
purposes. | 